Lahuerta Palacios, Juan José
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. [artículo] - Haematologica, 2012 - 97(4):616-21.
Formato Vancouver:
Rosiñol L, García-Sanz R, Lahuerta JJ, Hernández-García M, Granell M, de la Rubia J, et al. Benefit from autologous stem cell
transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica. 2012 Apr;97(4):616-21.
PMID: 22058223
Contiene 34 referencias
BACKGROUND: Several studies of autologous stem cell transplantation in primary refractory myeloma have produced encouraging results. However, the outcome of primary refractory patients with stable disease has not been analyzed separately from the outcome of patients with progressive disease.
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. [artículo] - Haematologica, 2012 - 97(4):616-21.
Formato Vancouver:
Rosiñol L, García-Sanz R, Lahuerta JJ, Hernández-García M, Granell M, de la Rubia J, et al. Benefit from autologous stem cell
transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica. 2012 Apr;97(4):616-21.
PMID: 22058223
Contiene 34 referencias
BACKGROUND: Several studies of autologous stem cell transplantation in primary refractory myeloma have produced encouraging results. However, the outcome of primary refractory patients with stable disease has not been analyzed separately from the outcome of patients with progressive disease.
